![]() |
½ÃÀ庸°í¼
»óǰÄÚµå
1789558
ÀÏȸ¿ë ÁÖ»ç±â ½ÃÀå : Á¦Ç° À¯Çüº°, Áö¿ªº°Disposable Syringes Market, By Product Type, and By Region |
ÀÏȸ¿ë ÁÖ»ç±â ½ÃÀåÀº 2025³â¿¡ 100¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, 2032³â¿¡´Â 156¾ï 4,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, 2025-2032³âÀÇ CAGRÀº 6.6%·Î ¼ºÀåÇÒ Àü¸ÁÀÔ´Ï´Ù.
¸®Æ÷Æ® ¹üÀ§ | ¸®Æ÷Æ® »ó¼¼ | ||
---|---|---|---|
±âÁØ¿¬µµ | 2024 | 2025³â ½ÃÀå ±Ô¸ð | 100¾ï ´Þ·¯ |
½ÇÀû µ¥ÀÌÅÍ | 2020-2024³â | ¿¹Ãø ±â°£ | 2025-2032³â |
¿¹Ãø ±â°£ : 2025-2032³â CAGR : | 6.60% | 2032³â °¡Ä¡ ¿¹Ãø | 156¾ï 4,000¸¸ ´Þ·¯ |
ÀÏȸ¿ë ÁÖ»ç±â´Â ÀÇ·á ¹× ¼öÀÇÇп¡¼ ÈçÈ÷ »ç¿ëµÇ´Â Åø·Î, ÇÃ¶ó½ºÆ½À¸·Î ±¸¼ºµÇ¾î ÀÖ½À´Ï´Ù. ÀÏȸ¿ë ÁÖ»ç±â´Â ¸ê±ÕµÈ »óÅ·Π¹Ù·Î »ç¿ëÇÒ ¼ö ÀÖ°í °¡°Ýµµ Àú·ÅÇØ ±âÁ¸ÀÇ À¯¸® ÁÖ»ç±â¸¦ ´ëüÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¡ÀÌÁî Àç¾ÓÀ¸·Î ÀÎÇØ ÁÖ»ç±â Àç»ç¿ëÀÌ »ç½Ç»ó ºÒ°¡´ÉÇØÁö¸é¼ ÀÏȸ¿ë ÁÖ»ç±â ¼ö¿ä°¡ ±ÞÁõÇϰí ÀÖ½À´Ï´Ù. ´ëºÎºÐÀÇ ÀÏȸ¿ë ÁÖ»ç±â´Â Æú¸®ÇÁ·ÎÇÊ·»À¸·Î ¸¸µé¾îÁö°í »çÃ⼺ÇüµË´Ï´Ù. ÁÖ»ç±â´Â 1ml, 2ml, 5ml, 10ml, ´Ù¾çÇÑ ¸ð¾çÀ¸·Î Á¦°øµÇ¸ç, µÎ°³ ¶Ç´Â ¼¼ °³ÀÇ ºÎǰÀ¸·Î ±¸¼ºµË´Ï´Ù. ÇÊ¿äÇÑ »çÃ⼺Çü±âÀÇ Å©±â¿Í ¼ö·®Àº ÁÖ»ç±â µðÀÚÀÎ, ±ÝÇü ijºñƼ ¼ö, ¿¬°£ »ý»ê·®¿¡ µû¶ó °áÁ¤µË´Ï´Ù. ¸¸¼ºÁúȯÀÇ ³ôÀº À¯º´·ü, Á¦Á¶ »ê¾÷ Áõ°¡, ÁÖ»çÁ¦¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡´Â ¿¹Ãø ±â°£ Áß ¼¼°è ÀÏȸ¿ë ÁÖ»ç±â ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù.
ÁÖ¿ä ½ÃÀå ±â¾÷Àº ÆÄÆ®³Ê½Ê ¹× Àμö¿Í °°Àº ¼ºÀå Àü·«À» äÅÃÇÏ´Â µ¥ ÁÖ·ÂÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ¼¼°è ÀÏȸ¿ë ÁÖ»ç±â ½ÃÀåÀÇ ¼ºÀå¿¡ ±â¿©Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2021³â 9¿ù, ¼ö¾× ¿ä¹ý ¹× ÁßȯÀÚ Ä¡·á ¿ëµµ¿¡ »ç¿ëµÇ´Â ÀåÄ¡¸¦ °³¹ß, Á¦Á¶, À¯Åë ¹× »óǰÈÇÏ´Â ÀÇ·á±â±â ȸ»çÀÎ ICU Medical, Inc.¿Í ´Ù°¢ÈµÈ ±â¼ú ȸ»çÀÎ Smiths Group plc. Bidco Ltd.¿¡ ´ëÇÑ Smiths MedicalÀÇ ±âÁ¸ ¸Å°¢¾ÈÀ» ¶Ù¾î³Ñ´Â °Å·¡·Î Smiths Medical ºÎ¹®À» ÀμöÇϱâ·Î ¾à¼ÓÇß´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. Smiths Medical »ç¾÷¿¡´Â ÁÖ»ç±â, ¿Ü·¡¿ë ¼ö¾× ÀåÄ¡, ¹Ù½ºÅ§·¯ ¾×¼¼½º, ¹ÙÀÌÅ»Äɾî Á¦Ç° µîÀÌ Æ÷ÇԵ˴ϴÙ. ICU MedicalÀÇ ±âÁ¸ »ç¾÷°ú ÅëÇյǸé ÅëÇÕ ÈÄ ±â¾÷ ¸ÅÃâÀº ¾à 25¾ï ´Þ·¯·Î ÃßÁ¤µÇ¸ç, ¼ö¾× Ä¡·áÀÇ ÁÖ¿ä ±â¾÷ÀÌ µÉ °ÍÀÔ´Ï´Ù.
º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡
Disposable Syringes Market is estimated to be valued at USD 10 Bn in 2025 and is expected to reach USD 15.64 Bn by 2032, growing at a compound annual growth rate (CAGR) of 6.6% from 2025 to 2032.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2024 | Market Size in 2025: | USD 10 Bn |
Historical Data for: | 2020 To 2024 | Forecast Period: | 2025 To 2032 |
Forecast Period 2025 to 2032 CAGR: | 6.60% | 2032 Value Projection: | USD 15.64 Bn |
Disposable Syringes are a common tool in the medical and veterinary sciences and are composed of plastic. Disposable syringes are quickly taking the place of traditional glass syringes since they are readily available in sterilized condition, ready to use, and are more affordable. Additionally, the scourge of AIDS has virtually eliminated the reuse of syringes, and the demand for disposable syringes has skyrocketed. Most disposable syringes are made of polypropylene and are injection molded. Syringes come in sizes of 1 ml, 2 ml, 5 ml, and 10 ml, come in a variety of shapes, and are either constructed of two or three components. The size and quantity of injection molding machines needed depend on the design of syringes, the number of mold cavities, and the annual production. The high prevalence of chronic diseases, the rising manufacturing, and the rising demand for injectable drugs is expected to boost the global disposable syringes market growth over the forecast period.
The key market players are focusing on adoption of growth strategies such as partnerships, as well as acquisitions, which is attributed to the growth of global disposable syringes market. For instance, in September 2021, ICU Medical, Inc., a medical device company which develops, manufactures, distributes and commercializes devices used in infusion therapy and critical care applications and Smiths Group plc., a diversified technology company announced that ICU Medical has committed to acquire the Smiths Medical division in a transaction that is superior to the existing proposed sale of Smiths Medical to Trulli Bidco Ltd. The Smiths Medical business includes syringe and ambulatory infusion devices, vascular access, and vital care products. When combined with ICU Medical's existing businesses, the combined companies will be a leading infusion therapy company with estimated pro forma combined revenues of approximately US$ 2.5 billion.
Key features of the study